News

Researchers have developed a new scale to assess disease severity in infants with Charcot-Marie-Tooth disease (CMT). The final version of the Charcot-Marie-Tooth disease Infant Scale (CMTInfS) is easy to use and very reliable to evaluate disease outcomes for early-onset CMT and other types of nerve disorders. The study supporting that assessment, “…

Investigational therapy ACE-083 was granted fast track designation for Charcot-Marie-Tooth disease (CMT) by the United States Food and Drug Administration, Acceleron Pharma recently announced. ACE-083 can prevent muscle shrinkage or atrophy that cause the debilitating symptoms of CMT disease by blocking the transforming growth…

 To help it reach its fundraising goal by year’s end, the Charcot-Marie-Tooth Association (CMTA) has issued its 35th Anniversary $150,000 Research Challenge. Donations will be matched dollar for dollar through Dec. 31, 2018. Fundraising totals are continually updated on the CMTA website.  Funds will go toward investigations…

To keep their balance while standing upright, children and adolescents with Charcot-Marie-Tooth (CMT) disease seem to adopt a more stiff posture and sway their bodies less than healthy individuals, researchers report. Their findings were published in the study, “Characterizing postural oscillation in children…

A newly launched international observational study is going to explore the overall impact of Charcot-Marie-Tooth disease (CMT) using a tailored app called CMT&Me. Designed by Vitaccess in collaboration with Pharnext, this new trial is expected to provide information on the disease’s medical, social, and economic impact, as…